{"id":35849,"date":"2025-10-06T10:32:42","date_gmt":"2025-10-06T08:32:42","guid":{"rendered":"https:\/\/ggba.swiss\/hemostod-raises-chf-4-3-million-to-scale-production-of-universal-blood-platelets\/"},"modified":"2025-10-06T10:35:29","modified_gmt":"2025-10-06T08:35:29","slug":"hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/","title":{"rendered":"HemostOD l\u00e8ve CHF 4,3 millions pour ses plaquettes sanguines universelles"},"content":{"rendered":"\n<p>Fond\u00e9e \u00e0 Lausanne, <a href=\"https:\/\/www.hemostod.com\/\">HemostOD<\/a> est pionni\u00e8re dans la production ex vivo de plaquettes \u00e0 partir de cellules souches h\u00e9matopo\u00ef\u00e9tiques immortalis\u00e9es et d\u2019une plateforme de bior\u00e9acteurs brevet\u00e9e. L\u2019entreprise entend r\u00e9pondre aux p\u00e9nuries r\u00e9currentes de plaquettes qui compromettent les traitements de patients atteints de cancer, victimes de traumatismes ou de troubles de la coagulation. En \u00e9liminant la d\u00e9pendance aux dons tout en am\u00e9liorant la qualit\u00e9 et la s\u00e9curit\u00e9, la technologie de plaquettes universelles d\u00e9velopp\u00e9e par HemostOD pourrait transformer durablement la m\u00e9decine transfusionnelle.<\/p>\n\n\n\n<p>La lev\u00e9e de fonds, co-dirig\u00e9e par <a href=\"https:\/\/www.polytechventures.ch\/\">Polytech Ventures<\/a> et Orenok Holdings, a \u00e9galement b\u00e9n\u00e9fici\u00e9 du soutien de la <a href=\"https:\/\/lichtsteinerfoundation.org\/\">Lichtsteiner Foundation<\/a> et d\u2019investisseurs priv\u00e9s. Ce financement porte \u00e0 CHF 6 millions le total des fonds lev\u00e9s par HemostOD depuis son tour de table initial en 2021.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">De la recherche de laboratoire \u00e0 l\u2019industrialisation<\/h4>\n\n\n\n<p>Les fonds serviront \u00e0 lancer une ligne pilote de production \u00e0 \u00e9chelle commerciale et \u00e0 pr\u00e9parer une r\u00e9union pr\u00e9-IND (pre-Investigational New Drug) avec la Food and Drug Administration (FDA) am\u00e9ricaine. Ces deux \u00e9tapes cl\u00e9s marquent une avanc\u00e9e d\u00e9cisive vers l\u2019engagement r\u00e9glementaire et la validation clinique.<\/p>\n\n\n\n<p>\u00ab Les p\u00e9nuries r\u00e9currentes de plaquettes compromettent la prise en charge m\u00e9dicale, du cancer aux traumatismes, un probl\u00e8me vital que nous sommes convaincus de pouvoir r\u00e9soudre \u00bb, explique Faouzi Khechana, CEO d\u2019HemostOD. \u00ab Ce financement marque un tournant majeur dans notre passage de la preuve de concept \u00e0 l\u2019industrialisation, nous rapprochant d\u2019une solution s\u00fbre et fiable pour les patients du monde entier. \u00bb<\/p>\n\n\n\n<p>Les investisseurs soulignent le potentiel scientifique et soci\u00e9tal de la soci\u00e9t\u00e9. \u00ab L\u2019approche innovante d\u2019HemostOD r\u00e9pond \u00e0 un besoin m\u00e9dical majeur et nous avons confiance en sa capacit\u00e9 \u00e0 passer \u00e0 l\u2019\u00e9chelle \u00bb, indique Guillaume Dubray, CEO de Polytech Ventures. Laurent Massuyeau, pr\u00e9sident d\u2019Orenok Holdings, ajoute : \u00ab La technologie d\u2019HemostOD ouvre la voie \u00e0 de multiples applications r\u00e9volutionnaires, de l\u2019h\u00e9matologie aux syst\u00e8mes avanc\u00e9s de d\u00e9livrance th\u00e9rapeutique. \u00bb<\/p>\n\n\n\n<p>Avec ce nouveau financement, HemostOD consolide sa position parmi les start-ups biotech les plus prometteuses de Suisse occidentale, en d\u00e9veloppant une solution universelle et durable aux d\u00e9fis mondiaux d\u2019approvisionnement en plaquettes sanguines.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HemostOD a r\u00e9uni CHF 4,3 millions dans le cadre d\u2019une lev\u00e9e de fonds destin\u00e9e \u00e0 acc\u00e9l\u00e9rer l\u2019industrialisation de ses plaquettes sanguines humaines universelles, produites sans recours aux dons. Ce financement marque une \u00e9tape cl\u00e9 pour la spin-off de l\u2019EPFL, qui passe d\u00e9sormais de la preuve de concept \u00e0 la production \u00e0 grande \u00e9chelle.<\/p>\n","protected":false},"author":6,"featured_media":35846,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1141,1142],"class_list":["post-35849","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-personalized-medicine-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CHF 4,3M pour les plaquettes sanguines universelles d&#039;HemostOD<\/title>\n<meta name=\"description\" content=\"HemostOD a r\u00e9uni CHF 4,3 millions pour acc\u00e9l\u00e9rer l\u2019industrialisation de ses plaquettes sanguines humaines universelles.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CHF 4,3M pour les plaquettes sanguines universelles d&#039;HemostOD\" \/>\n<meta property=\"og:description\" content=\"HemostOD a r\u00e9uni CHF 4,3 millions pour acc\u00e9l\u00e9rer l\u2019industrialisation de ses plaquettes sanguines humaines universelles.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-06T08:32:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-06T08:35:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/HemostOD-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"HemostOD l\u00e8ve CHF 4,3 millions pour ses plaquettes sanguines universelles\",\"datePublished\":\"2025-10-06T08:32:42+00:00\",\"dateModified\":\"2025-10-06T08:35:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/\"},\"wordCount\":391,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/HemostOD-1180x811-1.png\",\"keywords\":[\"Biotech\",\"Financing\",\"Personalized Medicine\",\"R&amp;D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/\",\"name\":\"CHF 4,3M pour les plaquettes sanguines universelles d'HemostOD\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/HemostOD-1180x811-1.png\",\"datePublished\":\"2025-10-06T08:32:42+00:00\",\"dateModified\":\"2025-10-06T08:35:29+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"HemostOD a r\u00e9uni CHF 4,3 millions pour acc\u00e9l\u00e9rer l\u2019industrialisation de ses plaquettes sanguines humaines universelles.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/HemostOD-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/HemostOD-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"HemostOD d\u00e9veloppe des plaquettes sanguines humaines sans donneur gr\u00e2ce \u00e0 sa technologie de bior\u00e9acteur propri\u00e9taire. | \u00a9 HemostOD\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HemostOD l\u00e8ve CHF 4,3 millions pour ses plaquettes sanguines universelles\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CHF 4,3M pour les plaquettes sanguines universelles d'HemostOD","description":"HemostOD a r\u00e9uni CHF 4,3 millions pour acc\u00e9l\u00e9rer l\u2019industrialisation de ses plaquettes sanguines humaines universelles.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/","og_locale":"fr_FR","og_type":"article","og_title":"CHF 4,3M pour les plaquettes sanguines universelles d'HemostOD","og_description":"HemostOD a r\u00e9uni CHF 4,3 millions pour acc\u00e9l\u00e9rer l\u2019industrialisation de ses plaquettes sanguines humaines universelles.","og_url":"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-10-06T08:32:42+00:00","article_modified_time":"2025-10-06T08:35:29+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/HemostOD-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"HemostOD l\u00e8ve CHF 4,3 millions pour ses plaquettes sanguines universelles","datePublished":"2025-10-06T08:32:42+00:00","dateModified":"2025-10-06T08:35:29+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/"},"wordCount":391,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/HemostOD-1180x811-1.png","keywords":["Biotech","Financing","Personalized Medicine","R&amp;D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/","url":"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/","name":"CHF 4,3M pour les plaquettes sanguines universelles d'HemostOD","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/HemostOD-1180x811-1.png","datePublished":"2025-10-06T08:32:42+00:00","dateModified":"2025-10-06T08:35:29+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"HemostOD a r\u00e9uni CHF 4,3 millions pour acc\u00e9l\u00e9rer l\u2019industrialisation de ses plaquettes sanguines humaines universelles.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/HemostOD-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/HemostOD-1180x811-1.png","width":1180,"height":811,"caption":"HemostOD d\u00e9veloppe des plaquettes sanguines humaines sans donneur gr\u00e2ce \u00e0 sa technologie de bior\u00e9acteur propri\u00e9taire. | \u00a9 HemostOD"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/hemostod-leve-chf-43-millions-pour-ses-plaquettes-sanguines-universelles\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"HemostOD l\u00e8ve CHF 4,3 millions pour ses plaquettes sanguines universelles"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/35849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=35849"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/35849\/revisions"}],"predecessor-version":[{"id":35851,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/35849\/revisions\/35851"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/35846"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=35849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=35849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=35849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}